• Mutation; VGNC; 54168; KDM6A; Simple; p.Thr986fs (c.2957delC); Zygosity=Homozygous (PubMed=31175136).
  

PubMed=20594083; DOI=10.2460/ajvr.71.7.799
McMahon M.B., Bear M.D., Kulp S.K., Pennell M.L., London C.A.
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
Am. J. Vet. Res. 71:799-808(2010)

PubMed=21621658; DOI=10.1016/j.bone.2011.05.008; PMCID=PMC3143255
Scott M.C., Sarver A.L., Gavin K.J., Thayanithy V., Getzy D.M., Newman R.A., Cutter G.R., Lindblad-Toh K., Kisseberth W.C., Hunter L.E., Subramanian S., Breen M., Modiano J.F.
Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.
Bone 49:356-367(2011)

PubMed=23311495; DOI=10.1186/1750-1172-8-7; PMCID=PMC3566973
Sarver A.L., Thayanithy V., Scott M.C., Cleton-Jansen A.-M., Hogendoorn P.C.W., Modiano J.F., Subramanian S.
MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma.
Orphanet J. Rare Dis. 8:7.1-7.11(2013)

PubMed=23365669; DOI=10.1371/journal.pone.0054464; PMCID=PMC3554772
Wells J.W., Evans C.H., Scott M.C., Rutgen B.C., O'Brien T.D., Modiano J.F., Cvetkovic G., Tepic S.
Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation.
PLoS ONE 8:E54464-E54464(2013)

PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)

PubMed=36099278; DOI=10.1371/journal.pone.0274383; PMCID=PMC9469990
Megquier K., Turner-Maier J., Morrill K., Li X., Johnson J., Karlsson E.K., London C.A., Gardner H.L.
The genomic landscape of canine osteosarcoma cell lines reveals conserved structural complexity and pathway alterations.
PLoS ONE 17:E0274383-E0274383(2022)